Mestinon

Mestinon - General Information

A cholinesterase inhibitor with a slightly longer duration of action than neostigmine. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants. [PubChem]

Pharmacology of Mestinon

Mestinon is a parasympathomimetic and a reversible cholinesterase inhibitor. Since it is a quaternary amine, it is poorly absorbed in the gut and doesn't cross the blood-brain barrier. Mestinon has a slightly longer duration of action than NEOSTIGMINE. It is used in the treatment of myasthenia gravis and to reverse the actions of muscle relaxants.

Mestinon for patients

Mestinon Interactions

No Information Provided.

Mestinon Contraindications

Mestinon is contraindicated in mechanical intestinal or urinary obstruction, and particular caution should be used in its administration to patients with bronchial asthma. Care should be observed in the use of atropine for counteracting side effects, as discussed below.

Additional information about Mestinon

Mestinon Indication: For the treatment of myasthenia gravis.
Mechanism Of Action: Mestinon inhibits acetylcholinesterase in the synaptic cleft by competing with acetylcholine for attachment to acetylcholinesterase, thus slowing down the hydrolysis of acetylcholine, and thereby increases efficiency of cholinergic transmission in the neuromuscular junction and prolonges the effects of acetylcholine.
Drug Interactions: Betamethasone The corticosteroid decreases the effect of anticholinesterases
Corticotropin The corticosteroid decreases the effect of anticholinesterases
Cortisone acetate The corticosteroid decreases the effect of anticholinesterases
Cosyntropin The corticosteroid decreases the effect of anticholinesterases
Dexamethasone The corticosteroid decreases the effect of anticholinesterases
Fludrocortisone The corticosteroid decreases the effect of anticholinesterases
Hydrocortisone The corticosteroid decreases the effect of anticholinesterases
Methylprednisolone The corticosteroid decreases the effect of anticholinesterases
Paramethasone The corticosteroid decreases the effect of anticholinesterases
Prednisolone The corticosteroid decreases the effect of anticholinesterases
Prednisone The corticosteroid decreases the effect of anticholinesterases
Succinylcholine The corticosteroid decreases the effect of anticholinesterases
Triamcinolone The corticosteroid decreases the effect of anticholinesterases
Food Interactions: Not Available
Generic Name: Pyridostigmine
Synonyms: Pyridostigmine Bromide; Pyridostigmine Bromine; Pyridostigminum; Pyridine N-Oxide
Drug Category: Antimyasthenics; Cholinesterase Inhibitors; Parasympathomimetics
Drug Type: Small Molecule; Approved

Other Brand Names containing Pyridostigmine: Mestinon; Regonol; Mestinon-SR;
Absorption: Poorly absorbed from the GI tract with an oral bioavailability of 7.6 +/- 2.4%.
Toxicity (Overdose): Not Available
Protein Binding: Not Available
Biotransformation: Hydrolysis by cholinesterases and by liver.
Half Life: 3 hours following oral administration.
Dosage Forms of Mestinon: Tablet Oral
Tablet, extended release Oral
Chemical IUPAC Name: (1-methylpyridin-1-ium-3-yl) N,N-dimethylcarbamate
Chemical Formula: C9H13N2O2+
Pyridostigmine on Wikipedia: https://en.wikipedia.org/wiki/Pyridostigmine
Organisms Affected: Humans and other mammals